Age-Related Blood Pressure Gradients Are Associated With Blood Pressure Control and Global Population Outcomes.

Autor:	Nolde JM; Dobney Hypertension Centre, Medical School, Royal Perth Hospital/Medical Research Foundation, University of Western Australia (J.M.N., R.C., M.P.S.).; Department of Nephrology, University of Freiburg Medical Centre, Germany (J.M.N.)., Beaney T; School of Public Health, Imperial College London, United Kingdom (T.B., N.R.P.)., Carnagarin R; Dobney Hypertension Centre, Medical School, Royal Perth Hospital/Medical Research Foundation, University of Western Australia (J.M.N., R.C., M.P.S.)., Stergiou GS; Hypertension Center STRIDE-7, National and Kapodistrian University of Athens, Third Department of Medicine, Sotiria Hospital, Greece (G.S.S.)., Poulter NR; School of Public Health, Imperial College London, United Kingdom (T.B., N.R.P.)., Schutte AE; School of Population Health, University of New South Wales, Australia (A.E.S.).; The George Institute for Global Health, Sydney, NSW, Australia (A.E.S.).; Hypertension in Africa Research Team, Medical Research Council Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa (A.E.S.)., Schlaich MP; Dobney Hypertension Centre, Medical School, Royal Perth Hospital/Medical Research Foundation, University of Western Australia (J.M.N., R.C., M.P.S.).; Departments of Cardiology and Nephrology (M.P.S.), Royal Perth Hospital, Australia.; Neurovascular Hypertension and Kidney Disease Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia (M.P.S.).
Jazyk:	angličtina
Zdroj:	Hypertension (Dallas, Tex. : 1979) [Hypertension] 2024 Oct; Vol. 81 (10), pp. 2091-2100. Date of Electronic Publication: 2024 Aug 07.
DOI:	10.1161/HYPERTENSIONAHA.124.23406
Abstrakt:	Background: The strong relationship between blood pressure (BP) and age is well known. Limited evidence suggests that a steeper age-BP slope may be associated with an increased risk of adverse outcomes. The May Measurement Month campaign enables an investigation of geographic, socioeconomic, and sex differences in age-related BP gradients and their association with public-health outcomes. Methods: Cross-sectional, annual global BP May Measurement Month screening data were analyzed. Average systolic BP and age-related BP slopes across different age groups were calculated to assess regional, socioeconomic, and sex-stratified variations. The association of BP slopes derived from adjusted linear regression models with country-level health metrics was investigated. Results: Age-related systolic BP gradients differed distinctly across global geographic regions, income levels, and between sexes. The steepest age gradients of BP were observed in populations from Africa and Europe. Women had lower BP levels than men at younger ages (20s and 30s) but subsequently experienced more pronounced age-related BP gradients. Geographically divergent age-related BP gradients were significantly associated with major national public health indicators. Globally, steeper age-related BP slopes were associated with poor BP control, increased disability-adjusted life years, and death rates. A steeper population age-BP slope of 1 mm Hg per 10 years was associated with a decrease in life expectancy of 3.3 years in this population (95% CI, -5.1 to -1.4; P =0.0007). Conclusions: Age-related BP gradients vary considerably across global populations and are associated with variability in BP-related risks and adverse outcomes across regions. Effective public health strategies may require region-specific targeting of adverse BP gradients to improve health outcomes. Competing Interests: A.E. Schutte has received speaker fees from Omron, Medtronic, Aktiia, Servier, Sanofi, and Novartis and is an advisory board member for Skylabs, Medtronic, and Abbott. M.P. Schlaich has received research support from Medtronic, Abbott, and Servier Australia. He serves on scientific advisory boards for Abbott, Boehringer Ingelheim, Servier, Novartis, and Medtronic and has received travel/speaker honoraria from Abbott, Medtronic, Lilly, and AstraZeneca. G.S. Stergiou has received speaker fees from AstraZeneca, Menarini, Omron, and Servier and consulting fees from Huawei, InBody, Microlife, Sanofi-Aventis, Skylabs, Sonion, and Viatris. The other authors report no conflicts.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu